Systemic Drug Safety Science
Multi-Organ Toxicity Screening and Systemic Safety Testing
A scientific overview of multi-organ toxicity assessment, why single-organ models miss systemic drug safety liabilities, and how integrated human microphysiological systems capture organ–organ crosstalk and metabolite-driven effects.
On this page
Definition
What is Multi-Organ Toxicity?
Multi-organ toxicity refers to drug-induced damage that affects more than one organ system — either through direct exposure or through secondary mechanisms such as circulating metabolites, inflammatory mediators, or disrupted organ–organ signalling. Many clinical safety signals that cause late-stage attrition or post-market withdrawal arise from systemic, multi-organ mechanisms that are invisible to single-organ in vitro models.
Multi-organ toxicity is most commonly observed in three contexts:
Metabolite-driven secondary toxicity
Hepatic metabolites circulate to downstream organs (e.g., brain, kidney) and cause toxicity not predicted by liver or target-organ models alone.
Systemic inflammatory responses
Cytokines and immune mediators released by one organ propagate injury cascades to distant tissues, exacerbating toxicity beyond the primary target.
Barrier and transport disruption
Disruption of intestinal, blood–brain, or renal barriers alters compound exposure to sensitive tissues in ways single-compartment models cannot predict.
For background on multi-organ platforms, see the Multi-Organ MPS page and the What is MPS? overview.
Model Limitations
Why Single-Organ Models Fail to Predict Systemic Toxicity
Isolated organ models
The overwhelming majority of preclinical in vitro safety assays test compounds in isolated organ models — liver cells for hepatotoxicity, neurons for neurotoxicity. This approach misses key systemic mechanisms:
- Hepatic metabolites that are toxic to the brain, kidney, or cardiovascular system are not generated in liver-free models and not delivered to brain or kidney models in isolated systems
- Gut barrier disruption, which alters systemic compound bioavailability, cannot be modelled without intestinal–liver coupling
- Inflammatory crosstalk between liver Kupffer cells and brain microglia — a key driver of metabolic encephalopathy — is entirely absent in single-organ formats
- Renal clearance of metabolites, which influences systemic exposure levels, is only captured in integrated liver–kidney models
Consequences for drug development
The absence of systemic toxicity prediction has real cost consequences. Compounds that pass single-organ in vitro safety screens regularly fail in animal studies or clinical trials due to unanticipated secondary organ toxicity — a problem that multi-organ in vitro systems are specifically designed to address.
- Up to 30% of late-stage drug failures are attributed to safety issues not captured by early in vitro screens
- Idiosyncratic multi-organ toxicity is among the most common causes of post-market withdrawal
- Regulatory agencies (FDA, EMA) increasingly accept human MPS data as supporting evidence in IND and NDA submissions
Model Requirements
What Makes a Good Multi-Organ In Vitro Model?
A multi-organ model for systemic toxicity assessment must satisfy a distinct set of requirements beyond single-organ platforms:
Key requirements for a predictive multi-organ model
- Physically separated organ compartments that allow independent sampling and endpoint measurement per organ
- Controlled biochemical communication between compartments — metabolite exchange without direct cell contact, replicating systemic circulation
- Organ-specific cell compositions maintained independently in each compartment (e.g., liver sinusoid complexity with hepatic stellate cells; brain multicellular network)
- Defined and reproducible flow or exchange conditions to support quantitative, reproducible inter-organ studies
- Compatibility with standard analytical readouts for each organ compartment
- Scalable format suitable for multi-compound studies and lead optimisation campaigns
NANOSTACKS™ Approach
How NANOSTACKS™ Supports Multi-Organ Safety Testing
Revivocell's Multi-Organ MPS platform uses modular NANOSTACKS™ inserts to build physically separated but biochemically coupled organ compartments within standard multiwell plates. Each organ module maintains its own validated cell composition while sharing a controlled medium exchange that mimics systemic metabolite circulation.
Key architectural features of the NANOSTACKS™ multi-organ platform:
Independent organ compartments
Each organ module (e.g., liver, brain) is maintained separately, allowing organ-specific readouts and endpoint sampling without cross-contamination.
Controlled medium transfer
Supernatant from upstream organ compartments is transferred to downstream compartments at defined ratios, replicating physiological metabolite circulation without direct cell mixing.
Orbital shaking dynamics
Physiological shear stress is generated without external pumps or complex microfluidic hardware, maintaining cell viability and function across all compartments simultaneously.
Modular configuration
Organ axes (e.g., Liver–Brain, Liver–Gut, Liver–Kidney) are assembled from validated individual organ modules, enabling flexible study design matched to specific research questions.
Organ Axis Configurations
Supported Organ Axes
| Organ Axis | Primary Use Case | Key Mechanistic Insight |
|---|---|---|
| Liver–Brain | Metabolite-driven neurotoxicity; CNS exposure modelling | Liver-generated metabolites delivered to neural compartment; detects secondary neurotoxicity invisible in isolated brain models |
| Liver–Gut | Intestinal metabolism and gut–liver signalling; first-pass effect modelling | Intestinal barrier contribution to hepatic exposure; bidirectional gut–liver crosstalk |
| Liver–Kidney | Renal clearance of hepatic metabolites; secondary nephrotoxicity | Downstream renal exposure to liver metabolites; metabolite-driven nephrotoxicity assessment |
| Custom combinations | Specialised multi-tissue safety questions | Configured per study objectives — contact the scientific team to discuss |
For connected barrier modelling across intestinal, blood–brain, and CSF barriers, see the Connected Barrier Modeling page.
Analytical Endpoints
Key Readouts and Endpoints
Multi-organ studies generate independent readouts per compartment alongside systemic (shared medium) measurements:
Liver compartment endpoints
- ALT / AST and LDH (hepatocyte injury)
- Albumin and urea synthesis (hepatic function)
- CYP enzyme activity and metabolite profiling (LC-MS/MS)
- Inflammatory cytokines from Kupffer cells (IL-6, TNF-α)
Brain compartment endpoints
- MEA spike rate and burst frequency (functional neurotoxicity)
- LDH and ATP (neuronal viability)
- Neurite morphology (high-content imaging)
- Inflammatory markers (IL-1β, GFAP upregulation)
Shared medium / systemic endpoints
- Metabolite concentrations at each transfer step
- Cytokine and signalling factor profiles
- Compound parent and metabolite quantification by HPLC-MS
Barrier and transport (where applicable)
- Transepithelial electrical resistance (TEER)
- Apparent permeability (Papp) for compound and metabolites
- Tight junction marker integrity (ZO-1, claudin, occludin imaging)
Drug Discovery Use Cases
Applications in Drug Discovery
Systemic ADME–toxicity integration
Combine hepatic metabolism, metabolite generation, and downstream organ toxicity in a single experimental platform — delivering a more complete systemic safety and ADME profile for IND-enabling packages.
Metabolite-driven secondary toxicity
Identify compounds where the parent drug is safe but liver-generated metabolites cause downstream CNS, renal, or cardiovascular toxicity — a safety risk entirely invisible in isolated organ models.
Organ crosstalk and systemic inflammation
Model how inflammatory signals generated in one organ (e.g., liver Kupffer cell cytokine release) propagate to exacerbate injury in distant tissues — relevant to immunotoxicology and complex drug safety profiles.
CNS drug exposure and neurotoxicity
For CNS candidates, integrate hepatic metabolism with blood–brain barrier modelling and functional neural readouts to assess compound CNS exposure, metabolite brain penetration, and direct neurotoxicity in a connected system.
New Approach Methodology (NAM) packages
Generate multi-organ human safety data under FDA Modernization Act 2.0 and EU NAM frameworks as a complement or replacement for multi-species in vivo toxicology studies.
Discuss a multi-organ study
Our team can advise on organ axis selection, study design, and interpretation of systemic safety data for your compounds.